Aptose Q2 net loss $14.1M; TUS/VEN doublet 50% CRc; Hanmi commits up to $7M

Aptose Biosciences Inc.

2023-Q2 EPS reported -$4.47

TUS/VEN doublet: 50% CRc (5/10 evaluable); 44% CRc in prior-venetoclax failures (4/9); 43% in FLT3-WT (3/7).
Hanmi Pharma commits up to $7M or 19.99% ownership in two tranches; first $3M by Aug-end conditional on TSX listing.
Q2 net loss $14.1M vs $10.6M prior year; cash $23.3M at June 30, expected to fund operations through March 2024.
FDA End of Phase 1 meeting completed; monotherapy RP2D of 80 mg daily confirmed; accelerated path remains open.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Aptose Biosciences Inc. reported three months ended June 30, 2023 results: net income $(14,129 ) thousand, EPS $(2.27 ) per share.

Period: three months ended June 30, 2023
Net income: $(14,129 ) thousand
EPS: $(2.27 ) per share
Result: reported results

Exact text from the filing

Aptose Reports Results for the Second Quarter 2023

View on SEC.gov

Browse all earnings releases →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-005225

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.